View ValuationBRAIN Biotech 将来の成長Future 基準チェック /16BRAIN Biotechは、45.5%と9.5%でそれぞれ年率45.5%で利益と収益が成長すると予測される一方、EPSはgrowで45.5%年率。主要情報45.5%収益成長率45.51%EPS成長率Chemicals 収益成長39.3%収益成長率9.5%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日05 May 2026今後の成長に関する最新情報お知らせ • Jan 17BRAIN Biotech AG Provides Revenue Guidance for the Year 2025/2026BRAIN Biotech AG provided revenue guidance for the year 2025/2026. For the financial year, BRAIN Biotech expects a small increase in group revenues vs. the previous financial year.Breakeven Date Change • Jan 16Forecast breakeven date moved forward to 2027The 5 analysts covering BRAIN Biotech previously expected the company to break even in 2028. New consensus forecast suggests losses will reduce by 64% to 2026. The company is expected to make a profit of €427.2k in 2027. Average annual earnings growth of 70% is required to achieve expected profit on schedule.Breakeven Date Change • Sep 30Forecast to breakeven in 2028The 4 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €4.49m in 2028. Average annual earnings growth of 78% is required to achieve expected profit on schedule.Breakeven Date Change • Jun 18No longer forecast to breakevenThe 4 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €1.53m in 2027. New consensus forecast suggests the company will make a loss of €95.3k in 2027.Breakeven Date Change • Feb 20No longer forecast to breakevenThe 3 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €7.03m in 2027. New consensus forecast suggests the company will make a loss of €3.65m in 2027.Breakeven Date Change • Nov 13Forecast breakeven date pushed back to 2027The 4 analysts covering BRAIN Biotech previously expected the company to break even in 2026. New consensus forecast suggests the company will make a profit of €8.80m in 2027. Average annual earnings growth of 67% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesお知らせ • May 12BRAIN Biotech AG to Report Fiscal Year 2026 Results on Jan 14, 2027BRAIN Biotech AG announced that they will report fiscal year 2026 results on Jan 14, 2027New Risk • Feb 26New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€728k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€9.6m free cash flow). Negative equity (-€728k). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€2.6m net loss in 2 years). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (€61.4m market cap, or US$72.4m).New Risk • Feb 05New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: €12m Forecast net loss in 3 years: €5.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€11m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€5.4m net loss in 3 years). Market cap is less than US$100m (€48.9m market cap, or US$57.7m).お知らせ • Feb 02BRAIN Biotech AG, Annual General Meeting, Mar 11, 2026BRAIN Biotech AG, Annual General Meeting, Mar 11, 2026, at 10:00 W. Europe Standard Time.New Risk • Jan 19New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: €12m Forecast net loss in 3 years: €5.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€11m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€5.4m net loss in 3 years). Market cap is less than US$100m (€52.9m market cap, or US$61.3m).お知らせ • Jan 17BRAIN Biotech AG Provides Revenue Guidance for the Year 2025/2026BRAIN Biotech AG provided revenue guidance for the year 2025/2026. For the financial year, BRAIN Biotech expects a small increase in group revenues vs. the previous financial year.Breakeven Date Change • Jan 16Forecast breakeven date moved forward to 2027The 5 analysts covering BRAIN Biotech previously expected the company to break even in 2028. New consensus forecast suggests losses will reduce by 64% to 2026. The company is expected to make a profit of €427.2k in 2027. Average annual earnings growth of 70% is required to achieve expected profit on schedule.New Risk • Nov 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (€80.0m market cap, or US$92.1m).お知らせ • Nov 18+ 1 more updateBRAIN Biotech AG to Report Q3, 2026 Results on Aug 27, 2026BRAIN Biotech AG announced that they will report Q3, 2026 results on Aug 27, 2026Breakeven Date Change • Sep 30Forecast to breakeven in 2028The 4 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €4.49m in 2028. Average annual earnings growth of 78% is required to achieve expected profit on schedule.Reported Earnings • Aug 28Third quarter 2025 earnings released: €0.028 loss per share (vs €0.12 loss in 3Q 2024)Third quarter 2025 results: €0.028 loss per share (improved from €0.12 loss in 3Q 2024). Revenue: €13.7m (up 1.6% from 3Q 2024). Net loss: €608.0k (loss narrowed 76% from 3Q 2024). Revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 18% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has fallen by 29% per year, which means it is performing significantly worse than earnings.Breakeven Date Change • Jun 18No longer forecast to breakevenThe 4 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €1.53m in 2027. New consensus forecast suggests the company will make a loss of €95.3k in 2027.お知らせ • May 29+ 1 more updateBRAIN Biotech AG to Report Fiscal Year 2025 Results on Jan 14, 2026BRAIN Biotech AG announced that they will report fiscal year 2025 results on Jan 14, 2026Reported Earnings • May 29Second quarter 2025 earnings released: €0.14 loss per share (vs €0.088 loss in 2Q 2024)Second quarter 2025 results: €0.14 loss per share (further deteriorated from €0.088 loss in 2Q 2024). Revenue: €12.5m (down 14% from 2Q 2024). Net loss: €3.06m (loss widened 60% from 2Q 2024). Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 12% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings.お知らせ • May 21BRAIN Biotech AG (XTRA:BNN) acquired remaining minority stake in Breatec B.V.BRAIN Biotech AG (XTRA:BNN) acquired remaining minority stake in Breatec B.V. on May 20, 2025. With the closure of this transaction, all businesses in the BRAINBiocatalysts division are now fully owned by BRAIN Biotech AG. BRAIN Biotech AG (XTRA:BNN) completed the acquisition of remaining minority stake in Breatec B.V. on May 20, 2025.Reported Earnings • Feb 27First quarter 2025 earnings released: €0.18 loss per share (vs €0.12 loss in 1Q 2024)First quarter 2025 results: €0.18 loss per share (further deteriorated from €0.12 loss in 1Q 2024). Revenue: €13.4m (up 3.4% from 1Q 2024). Net loss: €4.03m (loss widened 53% from 1Q 2024). Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 3.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.Breakeven Date Change • Feb 20No longer forecast to breakevenThe 3 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €7.03m in 2027. New consensus forecast suggests the company will make a loss of €3.65m in 2027.お知らせ • Feb 06BRAIN Biotech AG, Annual General Meeting, Mar 18, 2025BRAIN Biotech AG, Annual General Meeting, Mar 18, 2025, at 10:00 W. Europe Standard Time.お知らせ • Jan 19BRAIN Biotech AG to Report Q3, 2025 Results on Aug 28, 2025BRAIN Biotech AG announced that they will report Q3, 2025 results on Aug 28, 2025Reported Earnings • Jan 16Full year 2024 earnings released: €0.51 loss per share (vs €0.38 loss in FY 2023)Full year 2024 results: €0.51 loss per share (further deteriorated from €0.38 loss in FY 2023). Revenue: €56.0m (flat on FY 2023). Net loss: €11.1m (loss widened 34% from FY 2023). Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 3.6% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings.Breakeven Date Change • Nov 13Forecast breakeven date pushed back to 2027The 4 analysts covering BRAIN Biotech previously expected the company to break even in 2026. New consensus forecast suggests the company will make a profit of €8.80m in 2027. Average annual earnings growth of 67% is required to achieve expected profit on schedule.Reported Earnings • Aug 30Third quarter 2024 earnings released: €0.12 loss per share (vs €0.084 loss in 3Q 2023)Third quarter 2024 results: €0.12 loss per share (further deteriorated from €0.084 loss in 3Q 2023). Revenue: €13.6m (flat on 3Q 2023). Net loss: €2.57m (loss widened 39% from 3Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 5.7% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 45% per year, which means it is performing significantly worse than earnings.お知らせ • Aug 30BRAIN Biotech AG to Report First Half, 2025 Results on May 28, 2025BRAIN Biotech AG announced that they will report first half, 2025 results on May 28, 2025お知らせ • May 07BRAIN Biotech AG to Report Q1, 2025 Results on Feb 26, 2025BRAIN Biotech AG announced that they will report Q1, 2025 results on Feb 26, 2025Buy Or Sell Opportunity • Apr 08Now 25% undervaluedThe stock has been flat over the last 90 days, currently trading at €3.21. The fair value is estimated to be €4.27, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 2.7%. Revenue is forecast to grow by 39% in 2 years. Earnings are forecast to grow by 81% in the next 2 years.お知らせ • Mar 22BRAIN Biotech AG to Report Fiscal Year 2024 Results on Jan 15, 2025BRAIN Biotech AG announced that they will report fiscal year 2024 results on Jan 15, 2025Breakeven Date Change • Mar 19Forecast breakeven date pushed back to 2026The 4 analysts covering BRAIN Biotech previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 41% per year to 2025. The company is expected to make a profit of €2.28m in 2026. Average annual earnings growth of 65% is required to achieve expected profit on schedule.Reported Earnings • Sep 09Third quarter 2023 earnings released: €0.084 loss per share (vs €0.12 loss in 3Q 2022)Third quarter 2023 results: €0.084 loss per share (improved from €0.12 loss in 3Q 2022). Revenue: €13.5m (up 3.6% from 3Q 2022). Net loss: €1.84m (loss narrowed 30% from 3Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 6.4% decline forecast for the Chemicals industry in the United Kingdom.お知らせ • Sep 03BRAIN Biotech AG to Report Nine Months, 2024 Results on Aug 29, 2024BRAIN Biotech AG announced that they will report nine months, 2024 results on Aug 29, 2024Reported Earnings • Sep 02Third quarter 2023 earnings released: €0.084 loss per share (vs €0.12 loss in 3Q 2022)Third quarter 2023 results: €0.084 loss per share (improved from €0.12 loss in 3Q 2022). Revenue: €13.8m (up 5.7% from 3Q 2022). Net loss: €1.84m (loss narrowed 30% from 3Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 6.0% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.お知らせ • Aug 08BRAIN Biotech AG to Report First Half, 2024 Results on May 28, 2024BRAIN Biotech AG announced that they will report first half, 2024 results on May 28, 2024New Risk • Jun 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €90.9m (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Less than 1 year of cash runway based on current free cash flow (-€11m). Market cap is less than US$100m (€90.9m market cap, or US$99.6m).Reported Earnings • May 30Second quarter 2023 earnings released: €0.10 loss per share (vs €0.073 loss in 2Q 2022)Second quarter 2023 results: €0.10 loss per share (further deteriorated from €0.073 loss in 2Q 2022). Revenue: €13.8m (up 4.5% from 2Q 2022). Net loss: €2.27m (loss widened 42% from 2Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.0% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.お知らせ • May 26+ 2 more updatesBRAIN Biotech AG to Report Q1, 2024 Results on Feb 28, 2024BRAIN Biotech AG announced that they will report Q1, 2024 results on Feb 28, 2024お知らせ • May 25BRAIN Biotech AG (XTRA:BNN) acquired remaining 17.8% stake in Biocatalysts Limited.BRAIN Biotech AG (XTRA:BNN) acquired remaining 17.8% stake in Biocatalysts Limited on May 24, 2023. The minority stake purchases have been financed from existing BRAIN Biotech's cash reserves and from new debt.BRAIN Biotech AG (XTRA:BNN) completed the acquisition of remaining 17.8% stake in Biocatalysts Limited on May 24, 2023.Breakeven Date Change • May 19No longer forecast to breakevenThe 4 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €3.64m in 2025. New consensus forecast suggests the company will make a loss of €124.8k in 2025.Reported Earnings • Mar 02First quarter 2023 earnings released: €0.12 loss per share (vs €0.11 loss in 1Q 2022)First quarter 2023 results: €0.12 loss per share (further deteriorated from €0.11 loss in 1Q 2022). Revenue: €14.1m (up 36% from 1Q 2022). Net loss: €2.53m (loss widened 7.3% from 1Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 1.2% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Breakeven Date Change • Mar 02Forecast breakeven date moved forward to 2024The 4 analysts covering BRAIN Biotech previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 18% to 2023. The company is expected to make a profit of €650.0k in 2024. Average annual earnings growth of 104% is required to achieve expected profit on schedule.お知らせ • Jan 11BRAIN Biotech AG to Report Fiscal Year 2022 Results on Jan 16, 2023BRAIN Biotech AG announced that they will report fiscal year 2022 results on Jan 16, 2023お知らせ • Jan 10BRAIN Biotech AG Announces Executive ChangesBRAIN Biotech AG announced the appointments of two key leadership positions at its corporate site in Zwingenberg, headquarters and core biotechnology R&D campus of the international BRAIN Group. Following the announcement in October 2022, to establish an independent division for BRAIN Biotech AG's proprietary CRISPR technology announced that Dr. Alexander Pelzer will succeed Dr. Michael Krohn as Head of Research & Development. Dr. Krohn will now fully focus on his new leadership role with Akribion Genomics. Dr. Pelzer was previously Unit Head Enzymes & Biocatalysts at the company and has been with BRAIN Biotech for almost nine years. Dr. Pelzer enjoyed a broad education in biocatalysis, microbiology and molecular biology at the Research Centre Juelich with a focus on industrial enzyme technology. In addition to his experience in relevant fields, he demonstrated strong leadership skills along his whole career path. In addition, Dr. Martin Langer will expand his current business development responsibilities and will be appointed Managing Director and Executive Vice President of the BioScience segment at the Zwingenberg site. Dr. Langer was one of the first employees at BRAIN Biotech and accordingly has several decades of corporate experience. Alexander Pelzer and Martin Langer will take joint responsibility for further developing the R&D center in Zwingenberg into a customer-preferred provider for integrated biotechnology solutions.お知らせ • Nov 04BRAIN Biotech AG, Annual General Meeting, Mar 08, 2023BRAIN Biotech AG, Annual General Meeting, Mar 08, 2023.Breakeven Date Change • Oct 01Forecast to breakeven in 2025The 4 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €5.08m in 2025. Average annual earnings growth of 73% is required to achieve expected profit on schedule.Breakeven Date Change • Aug 24No longer forecast to breakevenThe 4 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €667.0k in 2024. New consensus forecast suggests the company will make a loss of €89.3k in 2024.Breakeven Date Change • Aug 09No longer forecast to breakevenThe 4 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €667.0k in 2024. New consensus forecast suggests the company will make a loss of €89.3k in 2024.Reported Earnings • Feb 27First quarter 2022 earnings: EPS in line with expectations, revenues disappointFirst quarter 2022 results: €0.11 loss per share (up from €0.19 loss in 1Q 2021). Revenue: €10.7m (up 29% from 1Q 2021). Net loss: €2.36m (loss narrowed 30% from 1Q 2021). Revenue missed analyst estimates by 2.3%. Over the next year, revenue is forecast to grow 15% compared to a 3.5% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Breakeven Date Change • Feb 04Forecast to breakeven in 2024The 5 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 19% per year to 2023. The company is expected to make a profit of €1.90m in 2024. Average annual earnings growth of 61% is required to achieve expected profit on schedule.Reported Earnings • Jan 20Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: €0.25 loss per share (up from €0.52 loss in FY 2020). Revenue: €40.7m (up 4.2% from FY 2020). Net loss: €4.97m (loss narrowed 49% from FY 2020). Revenue missed analyst estimates by 2.3%. Over the next year, revenue is forecast to grow 7.1% compared to a 3.6% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.Breakeven Date Change • Jan 17No longer forecast to breakevenThe 5 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €1.43m in 2024. New consensus forecast suggests the company will make a loss of €3.21m in 2024.Breakeven Date Change • Oct 01Forecast to breakeven in 2024The 5 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €1.43m in 2024. Average annual earnings growth of 61% is required to achieve expected profit on schedule.Reported Earnings • Sep 01Third quarter 2021 earnings released: €0.10 loss per share (vs €0.096 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: €10.1m (up 3.6% from 3Q 2020). Net loss: €2.03m (loss widened 16% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Breakeven Date Change • Jul 28No longer forecast to breakevenThe 6 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €1.12m in 2023. New consensus forecast suggests the company will make a loss of €701.5k in 2023.Reported Earnings • May 30Second quarter 2021 earnings released: EPS €0.10 (vs €0.14 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €11.2m (up 14% from 2Q 2020). Net income: €2.07m (up €4.56m from 2Q 2020). Profit margin: 18% (up from net loss in 2Q 2020). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.Reported Earnings • Mar 02First quarter 2021 earnings released: €0.19 loss per share (vs €0.13 loss in 1Q 2020)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: €8.41m (down 20% from 1Q 2020). Net loss: €3.36m (loss widened 49% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.Analyst Estimate Surprise Post Earnings • Jan 20Revenue misses expectationsRevenue missed analyst estimates by 5.9%. Over the next year, revenue is forecast to grow 8.8% compared to a 10% decline forecast for the Chemicals industry in the United Kingdom.Analyst Estimate Surprise Post Earnings • Jan 18Revenue misses expectationsRevenue missed analyst estimates by 5.9%. Over the next year, revenue is forecast to grow 12% compared to a 10% decline forecast for the Chemicals industry in the United Kingdom.Reported Earnings • Jan 16Full year 2020 earnings released: €0.52 loss per shareThe company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: €39.1m (down 2.5% from FY 2019). Net loss: €9.68m (loss narrowed 13% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings.業績と収益の成長予測LSE:0RFI - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/202864-5N/AN/A29/30/202763-5-7-449/30/202653-8-8-5312/31/202549-11-10-8N/A9/30/202550-12-11-9N/A6/30/202554-12-9-8N/A3/31/202554-14-7-5N/A12/31/202456-13-6-4N/A9/30/202456-11-5-4N/A6/30/202456-9-5-2N/A3/31/202456-8-4-2N/A12/31/202355-8-7-5N/A9/30/202356-8-7-4N/A6/30/202355-7-11-5N/A3/31/202354-7-11-6N/A12/31/202254-7-9-3N/A9/30/202250-7-8-1N/A6/30/202248-8-3-2N/A3/31/202244-8-4-1N/A12/31/202141-4-3-2N/A9/30/202139-5-5-4N/A6/30/202137-6-5-2N/A3/31/202137-6-6-5N/A12/31/202037-11-9-6N/A9/30/202039-10-8-5N/A6/30/202041-9-11-4N/A3/31/202041-12-11-5N/A12/31/201941-12-10-4N/A9/30/201940-11N/A-3N/A6/30/201939-9N/A-4N/A3/31/201937-7N/A-5N/A12/31/201833-7N/A-7N/A9/30/201829-8N/A-5N/A6/30/201827-9N/A-8N/A3/31/201825-8N/A-6N/A12/31/201726-7N/A-4N/A9/30/201726-10N/A-6N/A6/30/201726-14N/A-6N/A3/31/201726-14N/A-6N/A12/31/201625-17N/A-6N/A9/30/201625-15N/A-9N/A6/30/201624-10N/A-8N/A3/31/201624-9N/A-6N/A12/31/201524-7N/A-5N/A9/30/201524-6N/A-4N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 0RFI今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: 0RFI今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: 0RFI今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: 0RFIの収益 ( 9.5% ) UK市場 ( 4.5% ) よりも速いペースで成長すると予測されています。高い収益成長: 0RFIの収益 ( 9.5% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 0RFIの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 20:29終値2026/05/20 00:00収益2025/12/31年間収益2025/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BRAIN Biotech AG 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Yi-Dan WangDeutsche BankJan KochDeutsche BankJan KochDeutsche Bank5 その他のアナリストを表示
お知らせ • Jan 17BRAIN Biotech AG Provides Revenue Guidance for the Year 2025/2026BRAIN Biotech AG provided revenue guidance for the year 2025/2026. For the financial year, BRAIN Biotech expects a small increase in group revenues vs. the previous financial year.
Breakeven Date Change • Jan 16Forecast breakeven date moved forward to 2027The 5 analysts covering BRAIN Biotech previously expected the company to break even in 2028. New consensus forecast suggests losses will reduce by 64% to 2026. The company is expected to make a profit of €427.2k in 2027. Average annual earnings growth of 70% is required to achieve expected profit on schedule.
Breakeven Date Change • Sep 30Forecast to breakeven in 2028The 4 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €4.49m in 2028. Average annual earnings growth of 78% is required to achieve expected profit on schedule.
Breakeven Date Change • Jun 18No longer forecast to breakevenThe 4 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €1.53m in 2027. New consensus forecast suggests the company will make a loss of €95.3k in 2027.
Breakeven Date Change • Feb 20No longer forecast to breakevenThe 3 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €7.03m in 2027. New consensus forecast suggests the company will make a loss of €3.65m in 2027.
Breakeven Date Change • Nov 13Forecast breakeven date pushed back to 2027The 4 analysts covering BRAIN Biotech previously expected the company to break even in 2026. New consensus forecast suggests the company will make a profit of €8.80m in 2027. Average annual earnings growth of 67% is required to achieve expected profit on schedule.
お知らせ • May 12BRAIN Biotech AG to Report Fiscal Year 2026 Results on Jan 14, 2027BRAIN Biotech AG announced that they will report fiscal year 2026 results on Jan 14, 2027
New Risk • Feb 26New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€728k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€9.6m free cash flow). Negative equity (-€728k). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€2.6m net loss in 2 years). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (€61.4m market cap, or US$72.4m).
New Risk • Feb 05New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: €12m Forecast net loss in 3 years: €5.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€11m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€5.4m net loss in 3 years). Market cap is less than US$100m (€48.9m market cap, or US$57.7m).
お知らせ • Feb 02BRAIN Biotech AG, Annual General Meeting, Mar 11, 2026BRAIN Biotech AG, Annual General Meeting, Mar 11, 2026, at 10:00 W. Europe Standard Time.
New Risk • Jan 19New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: €12m Forecast net loss in 3 years: €5.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€11m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€5.4m net loss in 3 years). Market cap is less than US$100m (€52.9m market cap, or US$61.3m).
お知らせ • Jan 17BRAIN Biotech AG Provides Revenue Guidance for the Year 2025/2026BRAIN Biotech AG provided revenue guidance for the year 2025/2026. For the financial year, BRAIN Biotech expects a small increase in group revenues vs. the previous financial year.
Breakeven Date Change • Jan 16Forecast breakeven date moved forward to 2027The 5 analysts covering BRAIN Biotech previously expected the company to break even in 2028. New consensus forecast suggests losses will reduce by 64% to 2026. The company is expected to make a profit of €427.2k in 2027. Average annual earnings growth of 70% is required to achieve expected profit on schedule.
New Risk • Nov 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (€80.0m market cap, or US$92.1m).
お知らせ • Nov 18+ 1 more updateBRAIN Biotech AG to Report Q3, 2026 Results on Aug 27, 2026BRAIN Biotech AG announced that they will report Q3, 2026 results on Aug 27, 2026
Breakeven Date Change • Sep 30Forecast to breakeven in 2028The 4 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €4.49m in 2028. Average annual earnings growth of 78% is required to achieve expected profit on schedule.
Reported Earnings • Aug 28Third quarter 2025 earnings released: €0.028 loss per share (vs €0.12 loss in 3Q 2024)Third quarter 2025 results: €0.028 loss per share (improved from €0.12 loss in 3Q 2024). Revenue: €13.7m (up 1.6% from 3Q 2024). Net loss: €608.0k (loss narrowed 76% from 3Q 2024). Revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 18% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has fallen by 29% per year, which means it is performing significantly worse than earnings.
Breakeven Date Change • Jun 18No longer forecast to breakevenThe 4 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €1.53m in 2027. New consensus forecast suggests the company will make a loss of €95.3k in 2027.
お知らせ • May 29+ 1 more updateBRAIN Biotech AG to Report Fiscal Year 2025 Results on Jan 14, 2026BRAIN Biotech AG announced that they will report fiscal year 2025 results on Jan 14, 2026
Reported Earnings • May 29Second quarter 2025 earnings released: €0.14 loss per share (vs €0.088 loss in 2Q 2024)Second quarter 2025 results: €0.14 loss per share (further deteriorated from €0.088 loss in 2Q 2024). Revenue: €12.5m (down 14% from 2Q 2024). Net loss: €3.06m (loss widened 60% from 2Q 2024). Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 12% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings.
お知らせ • May 21BRAIN Biotech AG (XTRA:BNN) acquired remaining minority stake in Breatec B.V.BRAIN Biotech AG (XTRA:BNN) acquired remaining minority stake in Breatec B.V. on May 20, 2025. With the closure of this transaction, all businesses in the BRAINBiocatalysts division are now fully owned by BRAIN Biotech AG. BRAIN Biotech AG (XTRA:BNN) completed the acquisition of remaining minority stake in Breatec B.V. on May 20, 2025.
Reported Earnings • Feb 27First quarter 2025 earnings released: €0.18 loss per share (vs €0.12 loss in 1Q 2024)First quarter 2025 results: €0.18 loss per share (further deteriorated from €0.12 loss in 1Q 2024). Revenue: €13.4m (up 3.4% from 1Q 2024). Net loss: €4.03m (loss widened 53% from 1Q 2024). Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 3.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.
Breakeven Date Change • Feb 20No longer forecast to breakevenThe 3 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €7.03m in 2027. New consensus forecast suggests the company will make a loss of €3.65m in 2027.
お知らせ • Feb 06BRAIN Biotech AG, Annual General Meeting, Mar 18, 2025BRAIN Biotech AG, Annual General Meeting, Mar 18, 2025, at 10:00 W. Europe Standard Time.
お知らせ • Jan 19BRAIN Biotech AG to Report Q3, 2025 Results on Aug 28, 2025BRAIN Biotech AG announced that they will report Q3, 2025 results on Aug 28, 2025
Reported Earnings • Jan 16Full year 2024 earnings released: €0.51 loss per share (vs €0.38 loss in FY 2023)Full year 2024 results: €0.51 loss per share (further deteriorated from €0.38 loss in FY 2023). Revenue: €56.0m (flat on FY 2023). Net loss: €11.1m (loss widened 34% from FY 2023). Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 3.6% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings.
Breakeven Date Change • Nov 13Forecast breakeven date pushed back to 2027The 4 analysts covering BRAIN Biotech previously expected the company to break even in 2026. New consensus forecast suggests the company will make a profit of €8.80m in 2027. Average annual earnings growth of 67% is required to achieve expected profit on schedule.
Reported Earnings • Aug 30Third quarter 2024 earnings released: €0.12 loss per share (vs €0.084 loss in 3Q 2023)Third quarter 2024 results: €0.12 loss per share (further deteriorated from €0.084 loss in 3Q 2023). Revenue: €13.6m (flat on 3Q 2023). Net loss: €2.57m (loss widened 39% from 3Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 5.7% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 45% per year, which means it is performing significantly worse than earnings.
お知らせ • Aug 30BRAIN Biotech AG to Report First Half, 2025 Results on May 28, 2025BRAIN Biotech AG announced that they will report first half, 2025 results on May 28, 2025
お知らせ • May 07BRAIN Biotech AG to Report Q1, 2025 Results on Feb 26, 2025BRAIN Biotech AG announced that they will report Q1, 2025 results on Feb 26, 2025
Buy Or Sell Opportunity • Apr 08Now 25% undervaluedThe stock has been flat over the last 90 days, currently trading at €3.21. The fair value is estimated to be €4.27, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 2.7%. Revenue is forecast to grow by 39% in 2 years. Earnings are forecast to grow by 81% in the next 2 years.
お知らせ • Mar 22BRAIN Biotech AG to Report Fiscal Year 2024 Results on Jan 15, 2025BRAIN Biotech AG announced that they will report fiscal year 2024 results on Jan 15, 2025
Breakeven Date Change • Mar 19Forecast breakeven date pushed back to 2026The 4 analysts covering BRAIN Biotech previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 41% per year to 2025. The company is expected to make a profit of €2.28m in 2026. Average annual earnings growth of 65% is required to achieve expected profit on schedule.
Reported Earnings • Sep 09Third quarter 2023 earnings released: €0.084 loss per share (vs €0.12 loss in 3Q 2022)Third quarter 2023 results: €0.084 loss per share (improved from €0.12 loss in 3Q 2022). Revenue: €13.5m (up 3.6% from 3Q 2022). Net loss: €1.84m (loss narrowed 30% from 3Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 6.4% decline forecast for the Chemicals industry in the United Kingdom.
お知らせ • Sep 03BRAIN Biotech AG to Report Nine Months, 2024 Results on Aug 29, 2024BRAIN Biotech AG announced that they will report nine months, 2024 results on Aug 29, 2024
Reported Earnings • Sep 02Third quarter 2023 earnings released: €0.084 loss per share (vs €0.12 loss in 3Q 2022)Third quarter 2023 results: €0.084 loss per share (improved from €0.12 loss in 3Q 2022). Revenue: €13.8m (up 5.7% from 3Q 2022). Net loss: €1.84m (loss narrowed 30% from 3Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 6.0% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
お知らせ • Aug 08BRAIN Biotech AG to Report First Half, 2024 Results on May 28, 2024BRAIN Biotech AG announced that they will report first half, 2024 results on May 28, 2024
New Risk • Jun 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €90.9m (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Less than 1 year of cash runway based on current free cash flow (-€11m). Market cap is less than US$100m (€90.9m market cap, or US$99.6m).
Reported Earnings • May 30Second quarter 2023 earnings released: €0.10 loss per share (vs €0.073 loss in 2Q 2022)Second quarter 2023 results: €0.10 loss per share (further deteriorated from €0.073 loss in 2Q 2022). Revenue: €13.8m (up 4.5% from 2Q 2022). Net loss: €2.27m (loss widened 42% from 2Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.0% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
お知らせ • May 26+ 2 more updatesBRAIN Biotech AG to Report Q1, 2024 Results on Feb 28, 2024BRAIN Biotech AG announced that they will report Q1, 2024 results on Feb 28, 2024
お知らせ • May 25BRAIN Biotech AG (XTRA:BNN) acquired remaining 17.8% stake in Biocatalysts Limited.BRAIN Biotech AG (XTRA:BNN) acquired remaining 17.8% stake in Biocatalysts Limited on May 24, 2023. The minority stake purchases have been financed from existing BRAIN Biotech's cash reserves and from new debt.BRAIN Biotech AG (XTRA:BNN) completed the acquisition of remaining 17.8% stake in Biocatalysts Limited on May 24, 2023.
Breakeven Date Change • May 19No longer forecast to breakevenThe 4 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €3.64m in 2025. New consensus forecast suggests the company will make a loss of €124.8k in 2025.
Reported Earnings • Mar 02First quarter 2023 earnings released: €0.12 loss per share (vs €0.11 loss in 1Q 2022)First quarter 2023 results: €0.12 loss per share (further deteriorated from €0.11 loss in 1Q 2022). Revenue: €14.1m (up 36% from 1Q 2022). Net loss: €2.53m (loss widened 7.3% from 1Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 1.2% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Mar 02Forecast breakeven date moved forward to 2024The 4 analysts covering BRAIN Biotech previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 18% to 2023. The company is expected to make a profit of €650.0k in 2024. Average annual earnings growth of 104% is required to achieve expected profit on schedule.
お知らせ • Jan 11BRAIN Biotech AG to Report Fiscal Year 2022 Results on Jan 16, 2023BRAIN Biotech AG announced that they will report fiscal year 2022 results on Jan 16, 2023
お知らせ • Jan 10BRAIN Biotech AG Announces Executive ChangesBRAIN Biotech AG announced the appointments of two key leadership positions at its corporate site in Zwingenberg, headquarters and core biotechnology R&D campus of the international BRAIN Group. Following the announcement in October 2022, to establish an independent division for BRAIN Biotech AG's proprietary CRISPR technology announced that Dr. Alexander Pelzer will succeed Dr. Michael Krohn as Head of Research & Development. Dr. Krohn will now fully focus on his new leadership role with Akribion Genomics. Dr. Pelzer was previously Unit Head Enzymes & Biocatalysts at the company and has been with BRAIN Biotech for almost nine years. Dr. Pelzer enjoyed a broad education in biocatalysis, microbiology and molecular biology at the Research Centre Juelich with a focus on industrial enzyme technology. In addition to his experience in relevant fields, he demonstrated strong leadership skills along his whole career path. In addition, Dr. Martin Langer will expand his current business development responsibilities and will be appointed Managing Director and Executive Vice President of the BioScience segment at the Zwingenberg site. Dr. Langer was one of the first employees at BRAIN Biotech and accordingly has several decades of corporate experience. Alexander Pelzer and Martin Langer will take joint responsibility for further developing the R&D center in Zwingenberg into a customer-preferred provider for integrated biotechnology solutions.
お知らせ • Nov 04BRAIN Biotech AG, Annual General Meeting, Mar 08, 2023BRAIN Biotech AG, Annual General Meeting, Mar 08, 2023.
Breakeven Date Change • Oct 01Forecast to breakeven in 2025The 4 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €5.08m in 2025. Average annual earnings growth of 73% is required to achieve expected profit on schedule.
Breakeven Date Change • Aug 24No longer forecast to breakevenThe 4 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €667.0k in 2024. New consensus forecast suggests the company will make a loss of €89.3k in 2024.
Breakeven Date Change • Aug 09No longer forecast to breakevenThe 4 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €667.0k in 2024. New consensus forecast suggests the company will make a loss of €89.3k in 2024.
Reported Earnings • Feb 27First quarter 2022 earnings: EPS in line with expectations, revenues disappointFirst quarter 2022 results: €0.11 loss per share (up from €0.19 loss in 1Q 2021). Revenue: €10.7m (up 29% from 1Q 2021). Net loss: €2.36m (loss narrowed 30% from 1Q 2021). Revenue missed analyst estimates by 2.3%. Over the next year, revenue is forecast to grow 15% compared to a 3.5% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Feb 04Forecast to breakeven in 2024The 5 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 19% per year to 2023. The company is expected to make a profit of €1.90m in 2024. Average annual earnings growth of 61% is required to achieve expected profit on schedule.
Reported Earnings • Jan 20Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: €0.25 loss per share (up from €0.52 loss in FY 2020). Revenue: €40.7m (up 4.2% from FY 2020). Net loss: €4.97m (loss narrowed 49% from FY 2020). Revenue missed analyst estimates by 2.3%. Over the next year, revenue is forecast to grow 7.1% compared to a 3.6% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Jan 17No longer forecast to breakevenThe 5 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €1.43m in 2024. New consensus forecast suggests the company will make a loss of €3.21m in 2024.
Breakeven Date Change • Oct 01Forecast to breakeven in 2024The 5 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €1.43m in 2024. Average annual earnings growth of 61% is required to achieve expected profit on schedule.
Reported Earnings • Sep 01Third quarter 2021 earnings released: €0.10 loss per share (vs €0.096 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: €10.1m (up 3.6% from 3Q 2020). Net loss: €2.03m (loss widened 16% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Jul 28No longer forecast to breakevenThe 6 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €1.12m in 2023. New consensus forecast suggests the company will make a loss of €701.5k in 2023.
Reported Earnings • May 30Second quarter 2021 earnings released: EPS €0.10 (vs €0.14 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €11.2m (up 14% from 2Q 2020). Net income: €2.07m (up €4.56m from 2Q 2020). Profit margin: 18% (up from net loss in 2Q 2020). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Mar 02First quarter 2021 earnings released: €0.19 loss per share (vs €0.13 loss in 1Q 2020)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: €8.41m (down 20% from 1Q 2020). Net loss: €3.36m (loss widened 49% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.
Analyst Estimate Surprise Post Earnings • Jan 20Revenue misses expectationsRevenue missed analyst estimates by 5.9%. Over the next year, revenue is forecast to grow 8.8% compared to a 10% decline forecast for the Chemicals industry in the United Kingdom.
Analyst Estimate Surprise Post Earnings • Jan 18Revenue misses expectationsRevenue missed analyst estimates by 5.9%. Over the next year, revenue is forecast to grow 12% compared to a 10% decline forecast for the Chemicals industry in the United Kingdom.
Reported Earnings • Jan 16Full year 2020 earnings released: €0.52 loss per shareThe company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: €39.1m (down 2.5% from FY 2019). Net loss: €9.68m (loss narrowed 13% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings.